US EditionGroundbreaking Cancer Therapy Clinical Trial with U.S. Department of Energy’s Accelerator-Produced Actinium-225 Set to Begin this Summer
Summary by Newswise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
06:01 Belgian PanTera is allowed to build a site in Mol for the production of actinium-225, a sought-after but scarce radioactive substance that ‘big pharma’ is testing as a precision bombardment against cancer. ‘We have...
·Belgium
Read Full Article
Groundbreaking Cancer Therapy Clinical Trial with U.S. Department of Energy’s Accelerator-Produced Actinium-225 Set to Begin this Summer
The Department of Energy's (DOE) Isotope Program, within the Office of Science, will supply a U.S. based company with accelerator produced actinium-225 (Ac-225) in support of an upcoming U.S. clinical trial for cancer therapy for the first time. This is a significant milestone in the advancement of radiopharmaceutical development and cancer therapy because it opens a potential new pipeline for this lifesaving isotope.
·Charlottesville, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
